Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Aurora Cannabis

Flora Growth Corp

GrowGeneration Corp

HEXO Corp

Innovative Industrial Properties

WM Technology

Scotts Miracle-Gro

Village Farms International

22nd Century Group

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.

10 Marijuana Stocks Lighting Up With a Focus on Earnings

JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.

JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised

AbbVie

2 Marijuana Stocks That Have The Chance To See Better Trading The post 2 Marijuana Stocks That Could Soon Recover This Month appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Marijuana Stocks That Could Soon Recover This Month

Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Andrea Flynn – Head-Investor Relations Bruce Cozadd – Chairman and Chief Executive Officer Dan Swisher – President Rob Iannone – Executive Vice President, Global Head-R&D Renee Gala – Executive Vice President and Chief Financial Officer Kim Sablich – Executive Vice President and General Manager-North America Conference Call Participants Ken Cacciatore – Cowen Jessica Fye – JPMorgan Jason Gerberry – Bank of America Marc Goodman – SVB Leerink Brandon Folkes – Cantor Fitzgerald Jeff Hung – Morgan Stanley Balaji Prasad – Barclays Rob Palermo – Goldman Sachs Gary Nachman – BMO Capital Markets David Amsellem – Piper Sandler Annabel Samimy – Stifel Oren Livnat – H. C. Wainwright Greg Fraser – Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by.

Jazz Pharmaceuticals' (JAZZ) CEO Bruce Cozadd on Q1 2022 Results - Earnings Call Transcript

Jazz (JAZZ) delivered earnings and revenue surprises of -0.53% and 4.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Lags Q1 Earnings and Revenue Estimates

DUBLIN , May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2022, raised 2022 financial guidance and provided business updates. "We're pleased to raise our top- and bottom-line guidance, driven by our continued execution and significant progress across commercial and R&D in the first quarter, which positions us well for the rest of the year and to achieve Vision 2025," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance

Jazz licenses development and commercialization rights in U.S., Europe and other territories; Sumitomo Pharma retains rights in Japan, China and other Asia/Pacific territories Sumitomo Pharma to receive $50 million upfront payment Jazz continues to expand neuroscience pipeline and strengthen leadership in sleep medicine DUBLIN and OSAKA, Japan , May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) today announced that the companies have entered into an exclusive licensing agreement under which Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma's investigational DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders.

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist

DUBLIN , May 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2022 Global Healthcare Conference on Tuesday, May 10, 2022, at 12:40 p.m. PT / 3:40 p.m.

Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference

AFC Gamma

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Robinhood

Leafly Holdings

Trulieve Cannabis Corp.

Tilray Brands

The Cannabis Industry And Parts Of The Sector To Watch In 2022 The post The Best Marijuana Stocks In 2022 And The Different Cannabis Sectors To Watch Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

The Best Marijuana Stocks In 2022 And The Different Cannabis Sectors To Watch Right Now

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q1 Earnings Expected to Decline

Axsome Therapeutics

This biotech company may be on the verge of turning things around.

Why This Stock Could Double Your Money in 2022

Werewolf Therapeutics

Infinity Pharma

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

DUBLIN , April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022

There are cannabis stocks that have seen their shares rise this year if you know where to look.

3 Pot Stocks With Market Momentum

Top Medical Marijuana Stocks To Invest In For 2022 The post Looking For Long Term Cannabis Stocks To Buy? Top Marijuana Stocks To Invest In 2022 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Looking For Long Term Cannabis Stocks To Buy? Top Marijuana Stocks To Invest In 2022

Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.

JAZZ Inks Deal With Werewolf to Add Oncology Candidate

Novel, investigational drug JZP815 inhibited tumor growth in several RAS- and BRAF-mutated solid tumor models, and demonstrated enhanced activity when combined with other MAPK pathway inhibitors Jazz plans to submit an investigational new drug application (IND) for JZP815 this year DUBLIN , April 8, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and collaboration partner Redx Pharma (AIM: REDX) today presented data showing the pan-RAF kinase inhibitor, JZP815, was active in multiple RAF- and RAS-mutant tumor pre-clinical models, with a pharmacokinetic profile that may provide drug exposure required for target engagement in humans. "As a precision pan-RAF inhibitor with a differentiated mechanism of action, JZP815 is a promising drug candidate for several types of difficult-to-treat solid tumors, including colorectal cancer, non-small cell lung cancer, melanoma and ovarian cancer," said Rob Iannone, M.D.

Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types

Alibaba

Unlike with many meme stocks, there are some solid fundamentals behind these investments.

Forget GameStop and AMC: Buy These 2 Growth Stocks Instead

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ: HOWL) WTX-613. WTX-613 is a differentiated, conditionally-activated interferon-alpha (IFNα) INDUKINE molecule.

Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma

Shares of Werewolf Therapeutics Inc. jumped 10.8% in premarket trading on Thursday after the company announced a licensing deal with Jazz Pharmaceuticals Plc worth up to $1.2 billion. Jazz now has exclusive development and commercialization rights to Werewolf's preclinical immuno-oncology candidate and plans to submit the molecule for Food and Drug Administration approval in 2023.

Jazz, Werewolf sign licensing deal worth up to $1.2 billion

Werewolf to receive $15 million upfront payment, with potential for up to $1.26 billion in development, regulatory and sales milestone payments in addition to royalties on future net sales WTX-613 expands Jazz's robust oncology pipeline and represents first immuno-oncology program in company's R&D portfolio DUBLIN and CAMBRIDGE, Mass. , April 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Werewolf Therapeutics, Inc. (Nasdaq: HOWL) today announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule.

Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule

Amgen

Novocure

They're good picks for very different reasons.

3 Biotech Stocks to Buy in April

The pharmaceutical company specializes in neuroscience and oncology therapies, including some with cannabis compounds.

Why Jazz Pharmaceuticals Stock Rose 13.3% in March

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

News for Jazz Pharmaceuticals Stock (JAZZ)